Celltrion, Inc. 068270.KS Stock
Celltrion, Inc. Price Chart
Celltrion, Inc. 068270.KS Financial and Trading Overview
| Celltrion, Inc. stock price | 179000 KRW |
| Previous Close | 164100 KRW |
| Open | 164900 KRW |
| Bid | 165500 KRW x 0 |
| Ask | 165600 KRW x 0 |
| Day's Range | 163900 - 168400 KRW |
| 52 Week Range | 140384.61 - 206730.77 KRW |
| Volume | 440.82K KRW |
| Avg. Volume | 506.38K KRW |
| Market Cap | 23.7T KRW |
| Beta (5Y Monthly) | 0.354109 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 KRW |
| Forward Dividend & Yield | 375 (0.22%) |
| Ex-Dividend Date | December 28, 2022 |
| 1y Target Est | 229929 KRW |
068270.KS Valuation Measures
| Enterprise Value | 23.76T KRW |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | 1.87 |
| Price/Sales (ttm) | 10.086608 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 10.11 |
| Enterprise Value/EBITDA | 25.607 |
Trading Information
Celltrion, Inc. Stock Price History
| Beta (5Y Monthly) | 0.354109 |
| 52-Week Change | 11.54% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 206730.77 KRW |
| 52 Week Low | 140384.61 KRW |
| 50-Day Moving Average | 168410 KRW |
| 200-Day Moving Average | 166339.89 KRW |
068270.KS Share Statistics
| Avg. Volume (3 month) | 506.38K KRW |
| Avg. Daily Volume (10-Days) | 402.89K KRW |
| Shares Outstanding | 143.23M |
| Float | 108.66M |
| Short Ratio | N/A |
| % Held by Insiders | 23.17% |
| % Held by Institutions | 18.70% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | N/A |
| Trailing Annual Dividend Yield | N/A |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0.0885 |
| Last Split Factor | 1.04:1 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 24.87% |
| Operating Margin (ttm) | 29.80% |
| Gross Margin | 45.29% |
| EBITDA Margin | 39.48% |
Management Effectiveness
| Return on Assets (ttm) | 7.44% |
| Return on Equity (ttm) | 14.38% |
Income Statement
| Revenue (ttm) | 2.35T KRW |
| Revenue Per Share (ttm) | 16402.77 KRW |
| Quarterly Revenue Growth (yoy) | 12.40% |
| Gross Profit (ttm) | N/A |
| EBITDA | 927.84B KRW |
| Net Income Avi to Common (ttm) | 582.78B KRW |
| Diluted EPS (ttm) | N/A |
| Quarterly Earnings Growth (yoy) | 39.39% |
Balance Sheet
| Total Cash (mrq) | 540.26B KRW |
| Total Cash Per Share (mrq) | 3791.03 KRW |
| Total Debt (mrq) | 780.74B KRW |
| Total Debt/Equity (mrq) | 18.25 KRW |
| Current Ratio (mrq) | 2.015 |
| Book Value Per Share (mrq) | N/A |
Cash Flow Statement
| Operating Cash Flow (ttm) | 138.08B KRW |
| Levered Free Cash Flow (ttm) | -35865972736 KRW |
Profile of Celltrion, Inc.
| Country | South Korea |
| State | N/A |
| City | Incheon |
| Address | 23 Academy-ro |
| ZIP | N/A |
| Phone | 82 3 2850 5000 |
| Website | https://www.celltrion.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea. The company markets bio pharmaceuticals; generic pharmaceuticals; covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 for the treatment of asthma and urticaria that is in phase 3 clinical trial; CT-P17 for the treatment of autoimmune diseases which is in phase 3 clinical trial; CT-P16 for the treatment of non-small cell lung cancer and colon cancer that is in phase 3 clinical trial; CT-P41 for the treatment of osteoporosis and bone loss, which is in phase 3 clinical trial; CT-P43 for the treatment of psoriasis, crohn's disease, and ulcerative colitis that is in phase 3 clinical trial; CT-P42 for the treatment of diabetic macular edema, which is in phase 3 clinical trial; CT-P47 for the treatment of rheumatoid arthritis, which is in phase 3 clinical trial; CT-P27 for the treatment of pandemic/seasonal influenza that is in phase 2 clinical trial; and CT-G20 for the treatment of Cardiomyopathy that is in phase 1 clinical trial. The company was founded in 2002 and is headquartered in Incheon, South Korea.
Q&A For Celltrion, Inc. Stock
What is a current 068270.KS stock price?
Celltrion, Inc. 068270.KS stock price today per share is 179000 KRW.
How to purchase Celltrion, Inc. stock?
You can buy 068270.KS shares on the KSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Celltrion, Inc.?
The stock symbol or ticker of Celltrion, Inc. is 068270.KS.
Which industry does the Celltrion, Inc. company belong to?
The Celltrion, Inc. industry is Biotechnology.
How many shares does Celltrion, Inc. have in circulation?
The max supply of Celltrion, Inc. shares is 206.85M.
What is Celltrion, Inc. Price to Earnings Ratio (PE Ratio)?
Celltrion, Inc. PE Ratio is now.
What was Celltrion, Inc. earnings per share over the trailing 12 months (TTM)?
Celltrion, Inc. EPS is 0 KRW over the trailing 12 months.
Which sector does the Celltrion, Inc. company belong to?
The Celltrion, Inc. sector is Healthcare.